91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Recruitment has begun in the UK for a world-first study to investigate whether using different COVID-19 vaccines for first and second doses is as effective as using the same type of vaccine for both. .
-
on the UK government's new 'Com-Cov' study of over 800 patients, designed to test mixing doses of the Oxford and Pfizer COVID-19 vaccines, as well as different intervals between doses.
-
Dr. Murphy of 91黑料, provider of clinical services to Pfizer/BioNTech’s COVID vaccine program, discusses what it takes to conduct a vaccine trial of this scale.
-
Morgan Hill, Principal, Global Medical Communications, offers insights on the evolution of healthcare messaging and how 91黑料 is staying at the forefront of communicating healthcare messages and data.
-
With the COVID-19 pandemic, Brexit, and the rapidly approaching deadlines to comply with the new European Regulation on in vitro diagnostics (IVDR), IVD manufacturers will need to prepare for an ever-evolving clinical and regulatory landscape, and create mitigation strategies that allow for quick, agile changes to keep studies on track. Additionally, manufacturers will need to adopt a strategy to address gaps in meeting new regulations to avoid potential UK and European Union product availability issues. Understanding current guidance and adapted regulations is the first step to navigating the transformations undergoing the diagnostics field and the broader healthcare industry. In , Angela Brown and Nicole Cowan provide an overview of today’s regulatory setting and discuss how manufacturers can develop strategies to ensure a successful transition to comply with the IVDR by the 2022 deadline, including: overcoming the shortage of Notified Bodies; assessing product portfolios and quality systems; planning and implementing technical file remediation; and managing the IVD lifecycle.
-
An article discussing how the pandemic spread caused disruption but also a rapid deployment of solutions to ensure continuity in clinical trials and preserve and build resilience into ongoing research programmes.
-
Michael Pellegrino, SVP of Global Medical Communications, outlines research on patient involvement in the journal review process.
-
91黑料’s David Morse, VP, Global Regulatory Affairs Consulting Services talks to Business Insider on regulatory pathways for development of new vaccines and vaccine boosters to address emerging COVID-19 variants.
-
Michael Pellegrino, SVP of Global Medical Communications weighs in on how industry has increasingly recognised the benefits of different communications for specific purposes and audiences.
-
Testing transmission in the community
91黑料’s Dr. Andrew Garrett, Executive Vice President Scientific Operations, talks to Politico on clinical trials to test COVID-19 transmission in the community
